Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years old.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2024-08-15
DOI
https://doi.org/10.58347/tml.2024.1709c
Primary Topic
Sympathectomy and Hyperhidrosis Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Sympathectomy and Hyperhidrosis Treatments
article

Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

article en

Abstract

The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years old.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 66(1709)
Zero hunger
Openalex Percentile: Top 82%
Sympathectomy and Hyperhidrosis Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2024) | TGRS Research Map | TGRS